Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

NCT07210047 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ENROLLING_BY_INVITATION

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma Refractory

Interventions

BIOLOGICAL: HuL001-10 mg/kg
BIOLOGICAL: HuL001-15 mg/kg
DRUG: Lenalidomide and Dexamethasone

Sponsor

HuniLife Biotechnology, Inc.